ABL Diagnostics spotlights NGS for CMV resistance monitoring at SEIMC 2026

By AI, Created 1:30 PM UTC, May 22, 2026, /AGP/ – ABL Diagnostics will present a scientific poster at SEIMC 2026 on using next-generation sequencing to detect cytomegalovirus resistance mutations in patients treated with maribavir. The work underscores growing demand for sensitive tools to track antiviral resistance in transplant and other immunocompromised populations.

Why it matters: - Cytomegalovirus remains a major infectious threat in immunocompromised patients, especially transplant recipients. - Maribavir has expanded treatment options for refractory or resistant CMV infections. - Detecting low-frequency resistance mutations can help laboratories better track emerging antiviral resistance patterns. - NGS-based monitoring may improve virological surveillance in research settings and help inform future clinical management strategies.

What happened: - ABL Diagnostics announced a scientific poster for the SEIMC 2026 congress. - The poster is titled “Use of Next-Generation Sequencing for the Study of Cytomegalovirus Resistance Mutations in Patients Receiving Maribavir.” - Investigators from Hospital Clínic de Barcelona developed the study. - The work examines CMV antiviral resistance mutations in patients receiving maribavir therapy. - The study focuses on immunocompromised cohorts, including solid organ transplant and hematopoietic stem cell transplant recipients. - ABL Diagnostics said the poster will be presented at SEIMC 2026. - The company is based in Woippy, France.

The details: - The poster evaluates NGS before and after maribavir treatment. - The study looks at resistance-associated mutations in CMV. - The research highlights the limits of conventional sequencing for low-frequency variants. - The poster is available here: the scientific poster. - ABL Diagnostics supported the work with its CMV genotyping ecosystem. - The toolkit includes the DeepChek® Assay UL27 / UL51 / UL54 / UL56 / UL89 / UL97 Drug Resistance assay for amplification and CMV resistance mutation analysis. - The workflow also includes DeepChek® NGS library preparation optimized for Illumina sequencing platforms. - The software component is DeepChek® Software, CMV module, for automated analysis and interpretation of CMV antiviral resistance mutations. - Palex, ABL Diagnostics’ strategic partner in Spain, collaborated on the implementation. - ABL Diagnostics said the solutions were used to support the Barcelona team’s research. - The company said advanced sequencing and precise bioinformatic interpretation are becoming essential in translational research and epidemiological assessment of complex CMV infections in transplant populations.

Between the lines: - The poster points to a broader shift toward higher-sensitivity resistance testing as clinicians manage more complex CMV cases. - NGS can surface variants that may not be visible with standard methods, which matters when treatment decisions depend on early resistance detection. - The research use-only status of the wet-lab components means the workflow is positioned for research and surveillance, not direct diagnosis. - The CE-IVD-marked software indicates the analysis layer has a regulated clinical designation in covered markets.

What’s next: - ABL Diagnostics will present the poster at SEIMC 2026. - The company expects demand for NGS-based viral resistance testing to keep rising as transplant therapies expand globally. - ABL Diagnostics said it will continue advancing integrated molecular solutions for infectious disease genomics.

The bottom line: - The SEIMC 2026 poster gives ABL Diagnostics another platform to show how NGS could sharpen CMV resistance monitoring in high-risk patient groups.